File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Regulation of p21, MMP-1, and MDR-1 expression in human colon carcinoma HT29 cells by Tian Xian liquid, a Chinese medicinal formula, in vitro and in vivo
  • Basic View
  • Metadata View
  • XML View
TitleRegulation of p21, MMP-1, and MDR-1 expression in human colon carcinoma HT29 cells by Tian Xian liquid, a Chinese medicinal formula, in vitro and in vivo
 
AuthorsSze, SCW1
Wong, KL1
Liu, WK3
Ng, TB3
Wong, JH3
Cheung, HP1
Yow, CML2
Chu, ESM1
Liu, Q1
Hu, YM1
Tsang, KW1
Lee, WS1
Tong, Y1
 
KeywordsChinese medicine decoction
colon cancer
metastasis and multidrug resistance
proliferation
Tian-Xian liquid
 
Issue Date2011
 
PublisherSage Publications, Inc.. The Journal's web site is located at http://www.sagepub.com/journalsProdDesc.nav?prodId=Journal201510
 
CitationIntegrative Cancer Therapies, 2011, v. 10 n. 1, p. 58-69 [How to Cite?]
DOI: http://dx.doi.org/10.1177/1534735410378743
 
AbstractEthnopharmacological relevance. Tian-Xian liquid (TXL), a commercially available Chinese medicine decoction, has been used as an anticancer dietary agent for more than 10 years without reported side effects. Aim of the study. The safety and quality consistency of TXL and its mechanisms of action on antiproliferation, antimetastasis, and reversion of multidrug resistance (MDR) regimens were explored. Materials and methods. In this study, an atomic absorption spectrophotometer and reversed phase high performance liquid chromatography with photodiode array detection (HPLC-DAD) were used to evaluate the main toxic elements and the quality consistency among different batches of TXL extracts, respectively. HT29 human colon cancer cell line and tumor-bearing nude mice were used. TXL was provided by China-Japan Feida Union Company Limited. The effect of TXL on in vitro proliferation of HT29 human colon cancer cell line was examined. The percentages of treated cells distributed in different phases of the cell cycles were analyzed by flow cytometry. Antiproliferative effect after treatment with TXL was assessed by determination of the protein levels of p21, cyclinD1, PCNA, and cdk-2, which are the key regulators for cell cycle progression. Meanwhile, the protein levels of MMP-1 and MDR-1 (multidrug resistance protein-1) were also determined to assess the effect of TXL on antimetastasis and reversion of MDR regimen, respectively. Results. The contents of main toxic elements were lower in TXL extract compared with the standard set by the Department of Health of the Government of Hong Kong Special Administrative Region (SAR). Our HPLC results showed that the relative standard deviations of the amount of the 5 standards were less than 5% in different batches of TXL. Immunoblotting analysis revealed a dramatic induction of cyclin kinase inhibitor p21 as well as an inhibition of cyclinD1, PCNA, and cdk-2 in the TXL-treated in vitro models, thereby, impeding cell progression from G1/S phase. Results obtained from the in vivo study also demonstrated that TXL upregulated the protein level of p21 and downregulated the protein levels of MMP-1 and MDR-1. Conclusions. Results obtained from the present investigation not only demonstrate the safety and quality of TXL extract but also demonstrate that TXL possesses antiproliferative and antimetastatic activities and brings about reversion of MDR on HT29 cell and on xenografted tissue in tumor-implanted nude mice. © The Author(s) 2011.
 
ISSN1534-7354
2013 Impact Factor: 2.014
 
DOIhttp://dx.doi.org/10.1177/1534735410378743
 
ISI Accession Number IDWOS:000289157000006
Funding AgencyGrant Number
Seed Funding Programme for Applied Research200807160015
Small Project Funding200807176239
University of Hong Kong
China-Japan Feida Union Company Limited
Funding Information:

This research was supported in part by a grant from Seed Funding Programme for Applied Research (no. 200807160015), Small Project Funding (no. 200807176239), the University of Hong Kong, and the contract research funding from China-Japan Feida Union Company Limited.

 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorSze, SCW
 
dc.contributor.authorWong, KL
 
dc.contributor.authorLiu, WK
 
dc.contributor.authorNg, TB
 
dc.contributor.authorWong, JH
 
dc.contributor.authorCheung, HP
 
dc.contributor.authorYow, CML
 
dc.contributor.authorChu, ESM
 
dc.contributor.authorLiu, Q
 
dc.contributor.authorHu, YM
 
dc.contributor.authorTsang, KW
 
dc.contributor.authorLee, WS
 
dc.contributor.authorTong, Y
 
dc.date.accessioned2010-10-31T13:35:23Z
 
dc.date.available2010-10-31T13:35:23Z
 
dc.date.issued2011
 
dc.description.abstractEthnopharmacological relevance. Tian-Xian liquid (TXL), a commercially available Chinese medicine decoction, has been used as an anticancer dietary agent for more than 10 years without reported side effects. Aim of the study. The safety and quality consistency of TXL and its mechanisms of action on antiproliferation, antimetastasis, and reversion of multidrug resistance (MDR) regimens were explored. Materials and methods. In this study, an atomic absorption spectrophotometer and reversed phase high performance liquid chromatography with photodiode array detection (HPLC-DAD) were used to evaluate the main toxic elements and the quality consistency among different batches of TXL extracts, respectively. HT29 human colon cancer cell line and tumor-bearing nude mice were used. TXL was provided by China-Japan Feida Union Company Limited. The effect of TXL on in vitro proliferation of HT29 human colon cancer cell line was examined. The percentages of treated cells distributed in different phases of the cell cycles were analyzed by flow cytometry. Antiproliferative effect after treatment with TXL was assessed by determination of the protein levels of p21, cyclinD1, PCNA, and cdk-2, which are the key regulators for cell cycle progression. Meanwhile, the protein levels of MMP-1 and MDR-1 (multidrug resistance protein-1) were also determined to assess the effect of TXL on antimetastasis and reversion of MDR regimen, respectively. Results. The contents of main toxic elements were lower in TXL extract compared with the standard set by the Department of Health of the Government of Hong Kong Special Administrative Region (SAR). Our HPLC results showed that the relative standard deviations of the amount of the 5 standards were less than 5% in different batches of TXL. Immunoblotting analysis revealed a dramatic induction of cyclin kinase inhibitor p21 as well as an inhibition of cyclinD1, PCNA, and cdk-2 in the TXL-treated in vitro models, thereby, impeding cell progression from G1/S phase. Results obtained from the in vivo study also demonstrated that TXL upregulated the protein level of p21 and downregulated the protein levels of MMP-1 and MDR-1. Conclusions. Results obtained from the present investigation not only demonstrate the safety and quality of TXL extract but also demonstrate that TXL possesses antiproliferative and antimetastatic activities and brings about reversion of MDR on HT29 cell and on xenografted tissue in tumor-implanted nude mice. © The Author(s) 2011.
 
dc.description.natureLink_to_subscribed_fulltext
 
dc.identifier.citationIntegrative Cancer Therapies, 2011, v. 10 n. 1, p. 58-69 [How to Cite?]
DOI: http://dx.doi.org/10.1177/1534735410378743
 
dc.identifier.doihttp://dx.doi.org/10.1177/1534735410378743
 
dc.identifier.eissn1552-695X
 
dc.identifier.epage69
 
dc.identifier.hkuros197172
 
dc.identifier.isiWOS:000289157000006
Funding AgencyGrant Number
Seed Funding Programme for Applied Research200807160015
Small Project Funding200807176239
University of Hong Kong
China-Japan Feida Union Company Limited
Funding Information:

This research was supported in part by a grant from Seed Funding Programme for Applied Research (no. 200807160015), Small Project Funding (no. 200807176239), the University of Hong Kong, and the contract research funding from China-Japan Feida Union Company Limited.

 
dc.identifier.issn1534-7354
2013 Impact Factor: 2.014
 
dc.identifier.issue1
 
dc.identifier.openurl
 
dc.identifier.pmid20702488
 
dc.identifier.scopuseid_2-s2.0-79953704228
 
dc.identifier.spage58
 
dc.identifier.urihttp://hdl.handle.net/10722/127608
 
dc.identifier.volume10
 
dc.languageeng
 
dc.publisherSage Publications, Inc.. The Journal's web site is located at http://www.sagepub.com/journalsProdDesc.nav?prodId=Journal201510
 
dc.publisher.placeUnited States
 
dc.relation.ispartofIntegrative Cancer Therapies
 
dc.relation.referencesReferences in Scopus
 
dc.rightsIntegrative Cancer Therapies. Copyright © Sage Publications, Inc..
 
dc.subject.meshColonic Neoplasms - drug therapy - genetics - metabolism - pathology
 
dc.subject.meshCyclin-Dependent Kinase Inhibitor p21 - biosynthesis - genetics
 
dc.subject.meshDrugs, Chinese Herbal - adverse effects - chemistry - pharmacology
 
dc.subject.meshMatrix Metalloproteinase 1 - biosynthesis - genetics
 
dc.subject.meshP-Glycoprotein - biosynthesis - genetics
 
dc.subjectChinese medicine decoction
 
dc.subjectcolon cancer
 
dc.subjectmetastasis and multidrug resistance
 
dc.subjectproliferation
 
dc.subjectTian-Xian liquid
 
dc.titleRegulation of p21, MMP-1, and MDR-1 expression in human colon carcinoma HT29 cells by Tian Xian liquid, a Chinese medicinal formula, in vitro and in vivo
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Sze, SCW</contributor.author>
<contributor.author>Wong, KL</contributor.author>
<contributor.author>Liu, WK</contributor.author>
<contributor.author>Ng, TB</contributor.author>
<contributor.author>Wong, JH</contributor.author>
<contributor.author>Cheung, HP</contributor.author>
<contributor.author>Yow, CML</contributor.author>
<contributor.author>Chu, ESM</contributor.author>
<contributor.author>Liu, Q</contributor.author>
<contributor.author>Hu, YM</contributor.author>
<contributor.author>Tsang, KW</contributor.author>
<contributor.author>Lee, WS</contributor.author>
<contributor.author>Tong, Y</contributor.author>
<date.accessioned>2010-10-31T13:35:23Z</date.accessioned>
<date.available>2010-10-31T13:35:23Z</date.available>
<date.issued>2011</date.issued>
<identifier.citation>Integrative Cancer Therapies, 2011, v. 10 n. 1, p. 58-69</identifier.citation>
<identifier.issn>1534-7354</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/127608</identifier.uri>
<description.abstract>Ethnopharmacological relevance. Tian-Xian liquid (TXL), a commercially available Chinese medicine decoction, has been used as an anticancer dietary agent for more than 10 years without reported side effects. Aim of the study. The safety and quality consistency of TXL and its mechanisms of action on antiproliferation, antimetastasis, and reversion of multidrug resistance (MDR) regimens were explored. Materials and methods. In this study, an atomic absorption spectrophotometer and reversed phase high performance liquid chromatography with photodiode array detection (HPLC-DAD) were used to evaluate the main toxic elements and the quality consistency among different batches of TXL extracts, respectively. HT29 human colon cancer cell line and tumor-bearing nude mice were used. TXL was provided by China-Japan Feida Union Company Limited. The effect of TXL on in vitro proliferation of HT29 human colon cancer cell line was examined. The percentages of treated cells distributed in different phases of the cell cycles were analyzed by flow cytometry. Antiproliferative effect after treatment with TXL was assessed by determination of the protein levels of p21, cyclinD1, PCNA, and cdk-2, which are the key regulators for cell cycle progression. Meanwhile, the protein levels of MMP-1 and MDR-1 (multidrug resistance protein-1) were also determined to assess the effect of TXL on antimetastasis and reversion of MDR regimen, respectively. Results. The contents of main toxic elements were lower in TXL extract compared with the standard set by the Department of Health of the Government of Hong Kong Special Administrative Region (SAR). Our HPLC results showed that the relative standard deviations of the amount of the 5 standards were less than 5% in different batches of TXL. Immunoblotting analysis revealed a dramatic induction of cyclin kinase inhibitor p21 as well as an inhibition of cyclinD1, PCNA, and cdk-2 in the TXL-treated in vitro models, thereby, impeding cell progression from G1/S phase. Results obtained from the in vivo study also demonstrated that TXL upregulated the protein level of p21 and downregulated the protein levels of MMP-1 and MDR-1. Conclusions. Results obtained from the present investigation not only demonstrate the safety and quality of TXL extract but also demonstrate that TXL possesses antiproliferative and antimetastatic activities and brings about reversion of MDR on HT29 cell and on xenografted tissue in tumor-implanted nude mice. &#169; The Author(s) 2011.</description.abstract>
<language>eng</language>
<publisher>Sage Publications, Inc.. The Journal&apos;s web site is located at http://www.sagepub.com/journalsProdDesc.nav?prodId=Journal201510</publisher>
<relation.ispartof>Integrative Cancer Therapies</relation.ispartof>
<rights>Integrative Cancer Therapies. Copyright &#169; Sage Publications, Inc..</rights>
<subject>Chinese medicine decoction</subject>
<subject>colon cancer</subject>
<subject>metastasis and multidrug resistance</subject>
<subject>proliferation</subject>
<subject>Tian-Xian liquid</subject>
<subject.mesh>Colonic Neoplasms - drug therapy - genetics - metabolism - pathology</subject.mesh>
<subject.mesh>Cyclin-Dependent Kinase Inhibitor p21 - biosynthesis - genetics</subject.mesh>
<subject.mesh>Drugs, Chinese Herbal - adverse effects - chemistry - pharmacology</subject.mesh>
<subject.mesh>Matrix Metalloproteinase 1 - biosynthesis - genetics</subject.mesh>
<subject.mesh>P-Glycoprotein - biosynthesis - genetics</subject.mesh>
<title>Regulation of p21, MMP-1, and MDR-1 expression in human colon carcinoma HT29 cells by Tian Xian liquid, a Chinese medicinal formula, in vitro and in vivo</title>
<type>Article</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=1534-7354&amp;volume=&amp;spage=DOI:10.1177/1534735410378743&amp;epage=&amp;date=2010&amp;atitle=Regulation+of+p21,+MMP-1+and+MDR-1+expression+in+Human+colon+carcinoma+HT29+by+Tian+Xian+Liquid,+a+Chinese+Medicine+Formula,+in+vitro+and+in+vivo</identifier.openurl>
<description.nature>Link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1177/1534735410378743</identifier.doi>
<identifier.pmid>20702488</identifier.pmid>
<identifier.scopus>eid_2-s2.0-79953704228</identifier.scopus>
<identifier.hkuros>197172</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-79953704228&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>10</identifier.volume>
<identifier.issue>1</identifier.issue>
<identifier.spage>58</identifier.spage>
<identifier.epage>69</identifier.epage>
<identifier.eissn>1552-695X</identifier.eissn>
<identifier.isi>WOS:000289157000006</identifier.isi>
<publisher.place>United States</publisher.place>
</item>
Author Affiliations
  1. The University of Hong Kong Li Ka Shing Faculty of Medicine
  2. Hong Kong Polytechnic University
  3. Chinese University of Hong Kong